Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study
Authors' conclusion
Chronic HCV patients treated with DAA experienced lower rates of cardiovascular events and all-cause mortality than those without treatment. The reduction of VTE was the most significant impact of DAA treatment among the cardiovascular outcomes.
Study context
- Population
- Patients with chronic hepatitis C virus (HCV) infection (serum HCV antibody and HCV-RNA), multi-institutional electronic medical records41,565 with chronic HCV identified
- Participants
- 1,984 vs 413
- Exposure
- Direct acting antiviral (DAA) treatment vs no DAA treatment
- DAAn = 1,984
- Non-DAAn = 413reference
- Outcome
- ACS, heart failure (HF), venous thromboembolism (VTE), stroke, CV death, major adverse cardiovascular event (MACE) and all-cause mortality
- Follow-up
- 3-year follow-up
Methodological detailsmulti-institutional, inverse probability of treatment weighting
- Multi-institutional
- Inverse probability of treatment weighting
Main finding
As reported in the abstract
DAA vs Non-DAAHazard ratio (95% CI)P value
HF
0.65(0.44–0.97)
P = 0.035VTE
0.19(0.07–0.49)
P = 0.001MACE
0.73(0.59–0.92)
P = 0.007All-cause mortality
0.50(0.38–0.67)
P < 0.001Observational data: associations, not effects.
Original publication
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study. Eur Heart J Cardiovasc Pharmacother. Published 26 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →